Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma
Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma
复制标题
DOI：
10.1111/j.1742-1241.2008.01777.x
复制
发表时间：
2008-08-01
影响因子：
2.6
通讯作者：
Dou, K.
中科院分区：
文献类型：
--
作者：
Song, W.;Li, H.;Dou, K.
背景：虽然原始造血和神经干细胞标志物CD 133已知存在于肝细胞癌（HCC）的癌症干细胞（CSC）中，但CD 133对HCC患者切除术后预后的影响仍然有限。方法：收集63例HCC患者的手术切除标本。采用免疫组化方法分析CD 133蛋白的表达，并评价CD 133表达与患者临床病理特征、肿瘤复发和生存期的关系。结果：63例肝癌组织中，CD 133阳性肿瘤细胞较多。26例（41.3%）CD 133阳性表达。CD 133表达水平升高与肿瘤分级升高、疾病分期进展和血清甲胎蛋白水平升高相关。Kaplan-Meier分析表明，与CD 133低表达的患者相比，CD 133水平升高的患者的总生存期较短，复发率较高。多变量分析显示，CD 133表达增加是HCC患者生存和肿瘤复发的独立预后因素。结论：肝癌组织中存在CD 133阳性细胞的再活化。此外，增加的CD 133表达对应于HCC中的较高阶段肿瘤，因此指示患者的不良预后。这些数据支持CSC假说。
Backgroud: Although the primitive haematopoietic and neuronal stem cell marker CD133 is known to be present in cancer stem cells (CSCs) in hepatocellular carcinoma (HCC), the postresection prognostic impact of CD133 in HCC patients remains limited. Methods: Sixty-three resected specimens were collected from HCC patients. The expression of CD133 protein was analysed by immunohistochemistry and the association of CD133 expression with clinicopathological characteristics, tumour recurrence and survival of the patients was evaluated. Results: Immunohistochemical analysis of 63 HCC tissue specimens revealed that CD133 positive tumour cells were frequently present in HCC. Increased CD133 immunostaining was found in 26 specimens (41.3%). Increased CD133 expression levels were correlated with increased tumour grade, advanced disease stage, and elevated serum alpha-fetoprotein levels. Kaplan-Meier analysis indicated that patients with increased CD133 levels had shorter overall survival and higher recurrence rates compared with patients with low CD133 expression. Multivariate analyses revealed that increased CD133 expression was an independent prognostic factor for survival and tumour recurrence in patients with HCC. Conclusions: These findings suggest that reactivated CD133 positive cells are frequently present in HCC. Additionally, increased CD133 expression corresponds with higher stage tumours in HCC, thus indicating a poor prognosis for patients. These data support the CSC hypothesis.